Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclophosphamide and Topotecan in Refractory/Relapsed AML
NCT00003340Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Nov 1997
- Primary completion
- Feb 2000
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of topotecan, cyclophosphamide in acute myeloid leukemia (AML), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Nov 1997; status: completed.
02
Drugs
topotecancyclophosphamide
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00003340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003340.